Tyrosinase and cholinesterase inhibitory activities and molecular docking studies on apigenin and vitexin

Yıl 2020, Cilt: 50 Sayı: 3, 268 - 271, 30.12.2020

Esen Sezen Karaoğlan Mehmet Koca

Öz

Background and Aims: Apigenin and viteksin are two phytochemical compounds in flavone structure. In this study, tyrosinase and cholinesterase inhibitory effects of apigenin and vitexin were tested. Then, molecular docking studies were conducted on these molecules. Methods: Cholinesterase inhibition was evaluated by minor modifications of Ellman’s method and tyrosinase inhibition was evaluated by minor modifications of Masuda’s method. Docking simulations were performed using the Schrödinger software suite. Results: When apigenin and vitexin were compared, apigenin showed higher inhibitory effect against butyrylcholinesterase (54±1.7%) and tyrosinase (49.36±0.24%), vitexin showed a higher inhibitory effect against acetylcholinesterase (66±1.6%). Conclusion: When molecular interactions between tested compounds and inhibited enzymes were examined, it was observed that there were interactions especially between enzyme structures and benzopyran rings of these compounds and hydroxyl groups bound to these rings.

Anahtar Kelimeler

Apigenin, vitexin, enzyme inhibitory activity, molecular simulation

Kaynakça

• • Anand, P., & Singh, B. (2013). Cite as a review on cholinesterase inhibitors for Alzheimer’s disease. Archives of Pharmacal Research, 36 (4), 375–399.
• • Banks, W.A. (2009). Characteristics of compounds that cross the blood-brain barrier. BMC Neurology, 9 (1), 1–5.
• • Chang, T.S. (2009). An updated review of tyrosinase inhibitors. International Journal of Molecular Sciences, 10, 2440–2475.
• • Choi, J.S., Islam, M.N., Ali, M.Y., Kim, E.J., Kim, Y.M., & Jung, H.A. (2014). Effects of C-glycosylation on anti-diabetic, anti-Alzheimer’s disease and anti-inflammatory potential of apigenin. Food and Chemical Toxicology, 64, 27–33.
• • Dajas, F., Rivera-Megret, F., Blasina, F., Arredondo, F., Abin-Carriquiry, J.A., Costa, G., Echeverry, C., Lafon, L., Heizen, H., Ferreira, M., & Morquio, A. (2003). Neuroprotection by flavonoids. Brazilian Journal of Medical and Biological Research, 36, 1613–1620.
• • Ellman, G. L., Courtney, K. D., Andres, V., & Feather-Stone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology, 7, 88–95.
• • Erdogan Orhan, I., Khan, M.T.H. (2014). Flavonoid derivatives as potent tyrosinase inhibitors - a survey of recent findings between 2008-2013. Current Topics in Medicinal Chemistry, 14(12), 1486–1493.
• • Faria, A., Mateus, N., & Calhau, C. (2012). Flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions. Nutrition and Aging, 1, 89–97.
• • Grutzendler, J., & Morris, J. C. (2001). Cholinesterase inhibitors for Alzheimer’s disease. Drugs, 61(1), 41–52.
• • He, M., Min, J. W., Kong, W. L., He, X. H., Li, J. X., & Peng, B. W. (2016). A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia, 115, 74–85.
• • Jung, H. A., Karki, S., Kim, J. H., & Choi, J. S. (2015). BACE1 and cholinesterase inhibitory activities of Nelumbo nucifera embryos. Archives of Pharmacal Research, 38, 1178–1187.
• • Katalinic, M., Rusak, G., Barovic, J. D., Sinko, G., Jelic, D., Antolovic, R., & Kovarik, Z. (2010). Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. European Journal of Medicinal Chemistry, 45, 186–192.
• • Komloova, M., Musilek, K., Horova, A., Holas, O., Dohnal, V., Gunn- Moore, F., & Kuca, K. (2011). Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors-implications for early Myasthenia gravis treatment. Bioorganic & Medicinal Chemistry Letters, 21 (8), 2505–2509.
• • Lima, L. K. F., Pereira, S. K. S., Junior, R. S. S., Santos, F. P. S., Nascimento, A. S., Feitosa, C. M., Figuerêdo, J. S., Cavalcante, A. N., Araújo, E. C. C., & Rai, M. (2018). A brief review on the neuroprotective mechanisms of vitexin. BioMed Research International, 2018, 1–8. https://doi.org/10.1155/2018/4785089.
• • Masuda, T., Yamashita, D., Takeda, Y., & Yonemori, S. (2005). Screening for tyrosinase inhibitors among extracts of seashore plants and identification of potent inhibitors from Garcinia subelliptica. Bioscience, Biotechnology, and Biochemistry, 69, 197–201.
• • Meng, X.Y., Zhang, H.X., Mezei, M., & Cui, M. (2011). Molecular Docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157.
• • Morris, G. M., & Lim-Wilby, M. (2008). Molecular docking. Methods in Molecular Biology, 443, 365–382.
• • Nordberg, A., & Svensson, A. L. (1998). Cholinesterase inhibitors in the treatment of Alzheimer’s disease A comparison of tolerability and pharmacology. Drug Safety, 19(6), 465–480.
• • Seo, S.Y., Sharma, V. K., & Sharma, N. (2003). Mushroom tyrosinase: Recent prospects. Journal of Agricultural and Food Chemistry, 51, 2837–2853.
• • Sheeja Malar, D., Shafreen, R. B., Karutha Pandian, S. T., & Devi, K. P. (2017). Cholinesterase inhibitory, anti-amyloidogenic and neuroprotective effect of the medicinal plant Grewia tiliaefolia -An in vitro and in silico study. Pharmaceutical Biology, 55(1), 381–393.
• • Spandana, K. M. A., Bhaskaran, M., Karri, V. V.S. N. R., & Natarajan, J. (2020). A comprehensive review of nano drug delivery system in the treatment of CNS disorders. The Journal of Drug Delivery Science and Technology. https://doi.org/10.1016/j.jddst.2020.101628.
• • Ye, Y., Chou, G. X., Wang, H., Chu, J. H., & Yu, Z. L. (2010). Flavonoids, apigenin and icariin exert potent melanogenic activities in murine B16 melanoma cells. Phytomedicine, 18, 32–35.
• • Zhou, X., Wang, F., Zhou, R., Song, X., & Xie, M. (2017). Apigenin: A current review on its beneficial biological activities. Journal of Food Biochemistry, 41, e12376.
• • Zolghadri, S., Bahrami, A., Khan, M. T. H., Munoz-Munoz, J., Garcia- Molina, F., Garcia-Canovas, F., & Saboury, A. A. (2019). A comprehensive review on tyrosinase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 34 (1), 279–309.